Skip to content

Clinical trials

Terminated Phase 2 Leukemia, Myeloid, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Phase 2 Status: Terminated Clear all

146 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20031
20042
20053
200612
20073
20086
200913
201011
20118
20126
20138
20145
201512
20165
201712
20187
20195
20209
20216
20224
20232
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated146

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center12
Masonic Cancer Center, University of Minnesota10
M.D. Anderson Cancer Center7
Roswell Park Cancer Institute5
St. Jude Children's Research Hospital5
National Cancer Institute (NCI)4
Technische Universität Dresden4
Medical College of Wisconsin3
OHSU Knight Cancer Institute3
Washington University School of Medicine3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute146
Myelodysplastic Syndromes52
Precursor Cell Lymphoblastic Leukemia-Lymphoma46
Leukemia30
Congenital Abnormalities26
Leukemia, Lymphocytic, Chronic, B-Cell26
Lymphoma, Non-Hodgkin25
Hodgkin Disease23
Leukemia, Myelogenous, Chronic, BCR-ABL Positive22
Multiple Myeloma16

Trials

Showing 1 to 25 of 146. Each trial links to its page on Pharma Observatory.

46 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.